We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Advice on ingredients in nicotine-containing liquids in electronic cigarettes and refill containers.
Groups of ODS with their ozone-depleting potential.
Advice for medical professionals to follow when assessing drivers with drug or alcohol misuse or dependence.
Directory of current ICH Guidelines which have been implemented by the Medicines and Healthcare products Regulatory Agency.
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
Check the tariff classification for flavour pods.
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
Guidance for those producing, processing, consuming, importing or exporting chemicals covered by the Chemical Weapons Convention (CWC)
The Novel Psychoactive Substances Committee (NPSC) is seeking evidence for its review of the evidence of the misuse and harms of synthetic cathinones in the UK.
Further measures to be introduced to ensure patients who are prescribed montelukast for the treatment of asthma are informed of the risk of neuropsychiatric reactions
Describes a system to track prescribing of antipsychotics, antidepressants and other psychotropics for people with learning disabilities, autism or both.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).